Indacaterol (Arcapta Neohaler) for COPD
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Indacaterol (Arcapta Neohaler) for COPD
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1389
Article Code: 1389b
Date: April 30, 2012
Volume: 54
Pages: 33-35
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1389
Article Code: 1389b
Date: April 30, 2012
Volume: 54
Pages: 33-35
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
